LABP

Landos Biopharma, Inc. [LABP] Stock Forecast

Q: What is Landos Biopharma, Inc. stock symbol ?

Landos Biopharma, Inc. is a US stock, located in Blacksburg of Va and trading under the symbol LABP

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

LABP Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

EPS has been decreasing for the past 3 years (Yearly statements)

Does not have any significance market cap ($10.67M)

LABP has less than 1 year of cash runway

Top 10 Correlated ETFs

LABP

Top 10 Correlated Stocks

LABP

In the News

01:00 26 Mar 2023 LABP

3 Top Biotech Penny Stocks Under $3 To Watch Right Now

Biotech penny stocks to watch right now. The post 3 Top Biotech Penny Stocks Under $3 To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

09:02 26 Mar 2023 LABP

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

10:59 26 Mar 2023 LABP

Landos Biopharma, Inc.'s (LABP) CEO Tim Mayleben on Q3 2021 Results - Earnings Call Transcript

09:57 26 Mar 2023 LABP

Should You Buy Landos Biopharma (LABP) Ahead of Earnings?

Landos Biopharma (LABP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

07:00 26 Mar 2023 LABP

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus

Phase 1 trial initiation expected before yearend with topline results in 1H 2022

07:00 26 Mar 2023 LABP

Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor's Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism

BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases, today announced the publication of a peer-reviewed article titled “First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of the LANCL2 pathway in psoriasis” in Scientific Reports. The peer-reviewed publication demonstrates omilancor's therapeutic efficacy in animal models of psoriasis.

07:00 26 Mar 2023 LABP

Landos Biopharma to Participate in Two Upcoming Investor Conferences in September

BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos will participate in two upcoming virtual investor conferences in September.

07:00 26 Mar 2023 LABP

Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine

BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that it has entered into a research collaboration with Peter Calabresi, M.D., Director of the Multiple Sclerosis Center and Professor of Neurology at Johns Hopkins University (JHU) School of Medicine. This research funded by the National Institutes of Health (NIH) will focus on further validating the NLRX1 immunometabolic pathway in Multiple Sclerosis (MS).

07:00 26 Mar 2023 LABP

Landos Biopharma to Participate in Upcoming Investor Events

BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos and additional management team members will participate in the following investor events in August.

05:08 26 Mar 2023 LABP

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will present at the upcoming Raymond James Virtual Human Health Innovation Conference on Monday, June 21, 2021 at 2:00 PM EDT.

LABP Financial details

Company Rating

Neutral

Market Cap

10.67M

Income

-65.42M

Revenue

Book val./share

1.09

Cash/share

1.19

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

22 Mar 2023

P/E

-0.2

Forward P/E

PEG

-0.03

P/S

P/B

0.24

P/C

0.22

P/FCF

-0.2

Quick Ratio

8.77

Current Ratio

9.04

Debt / Equity

0.12

LT Debt / Equity

EPS (TTM)

-1.63

EPS next Y

EPS next Q

EPS this Y

-0.11%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

290%

SMA20

-28.95%

SMA50

-42.55%

SMA100

-32.5%

Inst Own

39.11%

Inst Trans

-14.55%

ROA

-109%

ROE

-93%

ROC

-1.24%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

45.88M

Shs Float

Target Price

52W Range

0.211-1.92

52W High

52W Low

RSI

39.8

Rel Volume

0.09

Avg Volume

446.69K

Volume

40.55K

Perf Week

3.52%

Perf Month

-28.78%

Perf Quarter

-59.23%

Perf Half Y

-66.46%

Beta

-1.12698

Volatility

0.01%, 0.05%

Prev Close

2.04%

Price

0.265

Change

5.08%

LABP Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31
Revenue per share	0	0	0	0.46
Net income per share	-0.26	-0.58	-0.77	-0.98
Operating cash flow per share	-0.3	-0.43	-0.59	-0.69
Free cash flow per share	-0.3	-0.43	-0.59	-0.7
Cash per share	0.02	2.16	0.72	2.32
Book value per share	0.04	-1.11	-1.38	1.95
Tangible book value per share	0.04	-1.11	1.14	1.95
Share holders equity per share	0.04	-1.11	-1.38	1.95
Interest debt per share	0	0.01	0	0.01
Market cap	277.24M	277.24M	469.96M	187.98M
Enterprise value	276.88M	267.43M	467.54M	179.68M
P/E ratio	-45.87	-20.59	-15.59	-4.89
Price to sales ratio	0	0	0	10.44
POCF ratio	-40.2	-28.08	-20.47	-6.95
PFCF ratio	-39.95	-27.64	-20.31	-6.84
P/B Ratio	277.24	-10.84	-8.7	2.46
PTB ratio	277.24	-10.84	-8.7	2.46
EV to sales	0	0	0	9.98
Enterprise value over EBITDA	-46.46	-20.48	-15.58	-4.75
EV to operating cash flow	-40.15	-27.08	-20.36	-6.64
EV to free cash flow	-39.9	-26.66	-20.2	-6.53
Earnings yield	-0.02	-0.05	-0.06	-0.2
Free cash flow yield	-0.03	-0.04	-0.05	-0.15
Debt to equity	1.8	-2.97	-0.21	0.22
Debt to assets	0.64	1.51	0.2	0.18
Net debt to EBITDA	0.06	0.75	0.08	0.22
Current ratio	1.39	16.56	2.71	5.55
Interest coverage	-1.98K	-43.72	0	-94.21
Income quality	1.14	0.73	0.76	0.7
Dividend Yield	0	0	0	0
Payout ratio	0	0	0	0
Sales general and administrative to revenue	0	0	0	0.85
Research and developement to revenue	0	0	0	2.31
Intangibles to total assets	0	0	0	0
Capex to operating cash flow	0.01	0.02	0.01	0.02
Capex to revenue	0	0	0	-0.02
Capex to depreciation	-0.54	-1.53	-1.32	-2.24
Stock based compensation to revenue	0	0	0	0.23
Graham number	0.5	3.81	4.89	6.56
ROIC	-20.57	-0.46	-0.72	-0.61
Return on tangible assets	-2.16	-0.27	-0.54	-0.41
Graham Net	0.01	-1.13	0.43	1.9
Working capital	696K	47.08M	18.85M	75.54M
Tangible asset value	1000K	-25.58M	44.74M	76.27M
Net current asset value	696K	-25.95M	18.58M	75.54M
Invested capital	0	0	0	0
Average receivables	0	1.05M	500	0
Average payables	0	1.87M	5.33M	10.76M
Average inventory	0	0	0	0
Days sales outstanding	0	0	0	0
Days payables outstanding	0	0	0	0
Days of inventory on hand	0	0	0	0
Receivables turnover	0	0	0	0
Payables turnover	0	0	0	0
Inventory turnover	0	0	0	0
ROE	-6.04	0.53	0.56	-0.5
Capex per share	0	-0.01	0	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric	2021-09-30	2021-12-31	2022-03-31	2022-06-30	2022-09-30
Revenue per share	0	0	0	0	0
Net income per share	-0.32	-0.6	-0.37	-0.28	-0.2
Operating cash flow per share	-0.3	-0.36	-0.41	-0.45	-0.19
Free cash flow per share	-0.3	-0.36	-0.41	-0.45	-0.19
Cash per share	2.57	2.7	1.83	1.38	1.19
Book value per share	2.35	2.27	1.54	1.28	1.09
Tangible book value per share	2.35	2.27	1.54	1.28	1.09
Share holders equity per share	2.35	2.27	1.54	1.28	1.09
Interest debt per share	0	0.01	0	0	0
Market cap	583.45M	161.47M	59.38M	29.3M	26.17M
Enterprise value	565.55M	153.16M	48.11M	10.06M	-2.71M
P/E ratio	-11.57	-2.01	-1	-0.65	-0.83
Price to sales ratio	0	0	0	0	0
POCF ratio	-49.26	-13.39	-3.6	-1.63	-3.46
PFCF ratio	-48.19	-13.43	-3.6	-1.63	-3.46
P/B Ratio	6.21	2.12	0.96	0.57	0.59
PTB ratio	6.21	2.12	0.96	0.57	0.59
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-45.04	-7.77	-3.32	-0.91	0.34
EV to operating cash flow	-47.75	-12.7	-2.92	-0.56	0.36
EV to free cash flow	-46.71	-12.74	-2.91	-0.56	0.36
Earnings yield	-0.02	-0.12	-0.25	-0.39	-0.3
Free cash flow yield	-0.02	-0.07	-0.28	-0.61	-0.29
Debt to equity	0.12	0.22	0.25	0.13	0.12
Debt to assets	0.11	0.18	0.2	0.11	0.11
Net debt to EBITDA	1.43	0.42	0.78	1.74	3.66
Current ratio	9.4	5.55	4.99	8.92	9.04
Interest coverage	0	-63.74	0	0	0
Income quality	0.94	0.6	1.11	1.59	0.96
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.02	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-5.5	0	-0.02	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	4.08	5.52	3.58	2.84	2.2
ROIC	-0.21	-0.32	-0.33	-0.76	0.68
Return on tangible assets	-0.12	-0.22	-0.19	-0.19	-0.16
Graham Net	2.29	2.21	1.45	1.22	1.06
Working capital	93.22M	75.54M	61.85M	51.53M	44.01M
Tangible asset value	93.92M	76.27M	62.1M	51.53M	44.01M
Net current asset value	93.14M	75.54M	61.85M	51.53M	44.01M
Invested capital	0	0	0	0	0
Average receivables	1000	0	0	0	0
Average payables	10.4M	11.51M	11.36M	7.26M	3.96M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.13	-0.26	-0.24	-0.22	-0.18
Capex per share	-0.01	0	0	0	0

LABP Frequently Asked Questions

What is Landos Biopharma, Inc. stock symbol ?

Landos Biopharma, Inc. is a US stock , located in Blacksburg of Va and trading under the symbol LABP

What is Landos Biopharma, Inc. stock quote today ?

Landos Biopharma, Inc. stock price is $0.265 today.

Is Landos Biopharma, Inc. stock public?

Yes, Landos Biopharma, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 446.69K
Market Capitalization 10.67M
Employee 46
CEO Mr. Gregory Oakes
Headquarters Blacksburg,VA,US
IPO Date 2021-02-04
Website https://landosbiopharma.com

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and LABP-104, an orally-active and systemically bioavailable small molecule therapeutic candidate that targets LANCL2 agonist for the treatment of systemic lupus erythematosus and rheumatoid arthritis (RA). Its preclinical candidates in development include LABP-66 is an oral and small molecule NOD-like pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA; LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; and LABP-111, an oral and small molecule LANCL2 pathway agonist for the treatment of nonalcoholic steatohepatitis and type 1 diabetes. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.